
Sign up to save your podcasts
Or


Send us Fan Mail
🎙️Join us as we return to complete our 2 part look at Multi Disciplinary Team meetings (Tumor Boards).
In our last episode we set the scene as to why they were set up.
🎙️In this episode we return with the wonderful Dr Nicky Thorp, consultant oncologist and Vice President of the Royal College of Radiologists.
🎙️Nicky has been leading a review of the MDT process to see if we can make them as good as possible.
Can we get the most out of these meetings to maximise outcomes for our patients.
They were designed to get the Lone Wolf running with the Pack🐺
Can we get the Pack running in the right direction🐺🐺🐺?
Could Asynchronous MDTs work?
Can we combine the talents of the many groups looking at optimising MDTs?
Much to discuss🤔
Enjoy
Send us Fan Mail
Join us as we discuss MDTs in this weeks episode!
Love them or hate them we are all part of cancer Multi-Disciplinary Team meetings (Tumor Boards).
Why did they start?
How have they improved cancer care?
Are they a delay to decisions?
If MDT is More Dull Tedium rather than Make Dynamic Treatments then this episode is for you!!
We talk to the wonderful Dr Nicky Thorp, consultant oncologist and vice president of the Royal College of Radiologists who has been part a programme to try and review MDTS.
A great episode that affect anyone in cancer care.
Enjoy!
Send us Fan Mail
Join us as we explore recent advances in lung cancer with the excellent Dr Tom Newsom-Davis.
Tom is a very welcome returning guest. He is the current Chair of BTOG - British Thoracic Oncology Group - and a medical oncologist specialising in lung cancer at the Chelsea & Westminster Hospital, London.
Tom is a superb speaker on the topic of lung cancer and he guides us through:
- Antibody drug conjugates
- T cell engagers - Tarlatumab
- Bi specifics and Tri specifics
Tom breaks the record for the amount of Toxic Payload namedrops for ADCs.
The future of lung cancer remains hugely exciting!
Enjoy
Send us Fan Mail
Welcome to the second part in of the Simply Oncology podcast, looking at perioperative colon cancer therapy.
We are back with the wonderful Professor Jenny Seligman from Leeds, St. James's Cancer Hospital.
In our last episode we looked at the series of FOXTROT trials and their impact in the colon cancer peri-op space.
In this next episode we look at the ARIEL trials.
We have a clear signal in the MMR deficient patient group. We also look at where the MMR proficient patient group may benefit.
All this and Jenny keeps us in our place throughout.
Enjoy!
Send us Fan Mail
Join us today for an amazing round up of the peri-operative space in colon cancer with the excellent Professor Jenny Seligmann from Leeds.
We discuss all aspects of the FOXTROT trials and where this peri-operative space.
With the AZURE trial reporting this weekend at ESMO we discuss the landscape in peri-operative management.
Send us Fan Mail
🎙️Join us as we finish our discussion through Kidney Cancer with the wonderful Professor Daniel Heng of Calgary,Canada🇨🇦
🎙️In this episode we focus on the Real World Evidence 🌎🔎 from the IMDC
🎙️what cane we learn from comparing complete response rates and durable responses between IO-IO therapy and IO-VEGF therapy🤔
🎙️What has Danny learned through setting up the IMDC and how to bring people with you?
🎙️What areas does Danny think need expanding in the future in Renal Cancer?
All this and more alongside some genuine laughter 😂with Danny
Enjoy!!!
Send us Fan Mail
🚨Join us today as we discuss all things kidney cancer !!
💥We are Hanging with the Heng! The legend that is Professor Daniel Heng (AKA DannyHeng tm) from The Albert Child Cancer Centre, Calgary, Canada🇨🇦
🎙️We hear how Danny Heng started the IMDC (International Metastatic renal cell carcinoma Database Consortium) prognostic score in advanced kidney cancer.
🎙️We discuss how the IMDC moved as prognostic score to then being part of stratification for modern metastatic kidney cancer trials.
🎙️IMDC now shapes what drugs we give for 1st line metastatic kidney cancer.
🙌🏽Kidney cancer survivals have quadrupled since the early Interferon era
💡We discuss biomarkers 🧭
💡We discuss more biomarkers - KIM 1, Clusters, Composite Biomarkers.
This was so much fun to record and an absolute privilege to have Danny on the Podcast🙌🏽
☀️ Enjoy ☀️
Send us Fan Mail
Join us as we complete our discussion on all things Acute Oncology Services with the superb Dr Caroline Wilson PhD FRCP from the The Christie NHS Foundation Trust.
🎙️We look at what future directions AOS will move into and what the challenges may be.
🎙️What are the BIG 5 AOS presentations?
🎙️Caroline stakes a claim for the need to change how we view the role of who manages acute oncology toxicities.
Enjoy
Send us Fan Mail
Welcome back - today we are discussing Acute Oncology Services and how they have evolved over the last 15 years.
Why were they set up ?
To give cancer patients support and care when they need it most - when they are admitted to hospital with problems.
Do you know your type 1 from your type 2 or 3 Acute oncology patient?
We talk all things AOS with the wonderful Dr Caroline Wilson from The Christie Hospital in Manchester.
What would your ideal Acute Oncology Service look like? Caroline tells us how she is building her new service.
Is yours the same as ours - probably not?
Do we need to loosen the oncology strings on SACT toxicity and encourage this to be a general medical issue.
All this and more - Enjoy!
Send us Fan Mail
Welcome back to part 2 of our 2 part special on the INTENSIFY trail in metastatic prostate cancer study. We welcome back the wonder Professor Simon Crabb and Dr Sarah Chamberlain from the University Hospital Southampton where they work n the medical oncology department treating urological cancers.
If you haven’t listened to part 1 please go check it out now where we set the foundations of the INTENSIFY trial.
Now lets get in to the science behind the INTENSIFY study looking at eh DECIPHER score and pTEN.
From the publisher's feed
Welcome to Simply Oncology.
Cancer is daunting for both patients and for clinical teams.
Dr John McGrane and Dr Michael Rowe are oncologists who want to break down the complex parts of…